1. 小米集团(01810.HK)发布玄戒O1旗舰处理器，采用第二代3nm先进工艺制程，将搭载于15S Pro、平 板7 Ultra、手表S4；小米YU 7今日正式发布，定位 "豪华高性能SUV"。 2. 恒瑞医药(01276.HK)昨日暗盘高开涨超27%，收盘涨32.24%，报58.25港元，成交额7.51亿港元。 3. 新华保险(01336.HK)出资100亿元认购国丰兴华鸿鹄志远二期私募证券投资基金。 金十数据整理：每日港股市场要闻速递（5月23日 周五） 个股新闻 4. BOSS直聘(02076.HK)：截至2025年3月31日总收入19.23亿元人民币，同比增加12.88%；归属于股东 净利润5.18亿元，同比增加111.53%。 5. 据港交所文件，友邦保险(01299.HK)于5月22日耗资2120万港元回购了32.5万股股份。 6. 新加坡微小核糖核酸(miRNA)技术公司Mirxes-B(02629.HK)今日挂牌，昨日暗盘交易时段一度涨超 40%。 7. 汇丰控股(00005.HK)于5月21日耗资1.522亿港元回购了160万股股份，并耗资3280万英镑在其他交易 所回购了总计370万股 ...

公司建议按于记录日期合资格股东每持有10股股份获发3股供股股份的基准以发行价每股供股股份0.1港 元进行供股，以筹集总金额介于约1470万港元至约1500万港元。 假设于记录日期或之前并无新发行股份或购回股份，认购事项及供股的估计所得款项总额以及所得款项 净额预计将分别为约8470万港元及8090万港元。 公司拟按如下方式运用认购事项及供股的所得款项净额：(a)约6530万港元用于偿付集团的应付款项， 包括：约3120万港元用于偿付集团的判决债务;约1550万港元用于偿付集团的贷款(包括估计利息);约360 万港元用于结付集团的逾期雇员薪资;约510万港元用于结付若干逾期专业费用(与认购事项及供股相关 者除外);约990万港元用于结付逾期董事薪酬;(b)余额约1560万港元用作集团的营运资金。 智通财经APP讯，中国卫生集团(00673)发布公告，公司拟进行认购事项及供股，以应对集团的财务挑战 及解决资本需求，以支持持续运营及未来发展。 于2025年4月30日，公司订立认购协议A、认购协议B及认购协议C，内容有关按认购价每股认购股份0.1 港元向认购人A(Ample Colour Limited)、认购人B( ...

Financial Performance - For the six months ended September 30, 2024, the company reported a loss attributable to owners of the company of HKD 17,387,000, compared to a loss of HKD 15,060,000 in the same period of 2023, representing an increase in loss of approximately 15.5%[4] - Revenue for the six months ended September 30, 2024, was HKD 18,680,000, a decrease of 29.5% from HKD 28,268,000 in the same period of 2023[8] - Gross profit for the period was HKD 1,993,000, down 60.5% from HKD 5,035,000 in the previous year[8] - The company reported a total comprehensive loss of HKD 18,130 for the period, which includes a loss of HKD 17,387[32] - Revenue for the period was approximately HKD 13,200,000, a decrease of 39% compared to HKD 21,800,000 in the previous fiscal period[93] - The company recorded an operating loss of approximately HKD 700,000 for the period, an improvement from an operating loss of HKD 1,300,000 in the previous year[93] - The group recorded an operating loss of approximately HKD 3,200,000 for the hospital operations segment, compared to HKD 3,100,000 in the previous year[95] - The company has incurred an operating loss of approximately HKD 1,700,000 from its commercial factoring business during the reporting period, compared to a loss of HKD 600,000 in 2023[121] Cash Flow and Liquidity - The company reported a net cash outflow from operating activities of HKD 11,538,000 for the six months ended September 30, 2024, compared to an outflow of HKD 14,890,000 in the same period of 2023[13] - The company’s cash and cash equivalents decreased to HKD 2,409,000 from HKD 4,013,000 as of March 31, 2024, reflecting a decline of 40%[13] - The group’s current assets and net current assets were approximately HKD 124,900,000 and HKD 9,600,000, respectively, as of September 30, 2024[168] - The current ratio as of September 30, 2024, was 1.08, compared to 1.15 as of March 31, 2024[168] - The asset-liability ratio was 0.83 as of September 30, 2024, significantly higher than 0.11 as of March 31, 2024[169] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 187,157,000, a decrease from HKD 192,316,000 as of March 31, 2024[10] - The company’s total liabilities increased to HKD 135,607,000 as of September 30, 2024, compared to HKD 132,563,000 as of March 31, 2024[11] - The company’s equity attributable to owners decreased to HKD 49,164,000 from HKD 47,899,000 as of March 31, 2024, indicating a slight increase of 2.6%[11] - As of September 30, 2024, the company had other payables of HKD 64,012,000, an increase from HKD 34,960,000 as of March 31, 2024[62] - The company has a provision of $4,000,000 (approximately HKD 31,100,000) included in other payables and accrued expenses as of September 30, 2024[191] Revenue Breakdown - Revenue from medical device and consumables distribution and services was HKD 13,209,000, down 39.4% from HKD 21,808,000 year-on-year[45] - The company provided hospital operation and management services revenue of HKD 5,471,000, down 15.3% from HKD 6,460,000 in the previous year[45] - Revenue from hospital operations and management services was approximately HKD 5,500,000, compared to HKD 6,500,000 in the previous year[115] - Revenue from China was HKD 18,680, a decrease of 33.4% compared to HKD 28,268 in the same period of 2023[23] Shareholder Information - The company reported a shareholder loss of approximately HKD 17,400,000 for the period, compared to HKD 15,100,000 in the previous fiscal period, with a basic loss per share of HKD 0.0354 (previous year: HKD 0.0319)[92] - The total number of shares issued as of the reporting date is 484,249,000[181] - The company issued 12,650,000 new shares at a subscription price of HKD 0.8 per share, completed on July 17, 2024[88] - The group raised approximately HKD 10,100,000 from the placement and subscription of 12,650,000 shares, with a net amount of approximately HKD 9,800,000 for general working capital[166] Operational Focus and Strategy - The company continues to focus on its operational segments, including the distribution and service of medical devices and consumables, commercial services, and the research and sale of functional foods[18] - The management is actively working to streamline operations and recover receivables while seeking new investors to improve cash flow[102] - The company plans to continue focusing on building a nationwide healthcare distribution platform, leveraging recent government stimulus policies to enhance core competitiveness[125] - The company has entered into a cooperation framework agreement with Wuhan Mingcheng Wangda Pharmaceutical Co., Ltd. for comprehensive distribution projects in the healthcare sector[157] Acquisitions and Investments - The group completed the acquisition of 100% equity in Jinmei Development Limited for HKD 146,000,000, paid through the issuance of promissory notes[100] - The acquisition of 51% of Golden Alliance Limited was completed on June 16, 2023, for a total consideration of HKD 153,000,000[131] - The initial consideration for the acquisition of 100% of Putian Fuxin Molecular Diagnostics Co., Ltd. is HKD 46,666,667, with potential additional consideration of HKD 9,333,333 based on profit conditions[134] - The acquisition of 100% equity in Putian Fuxin (Tianjin) Molecular Diagnostic Technology Co., Ltd. is still pending completion[163] Employee and Operational Metrics - As of September 30, 2024, the group employed 118 staff members, down from 127 as of March 31, 2024[193] - Total employee costs, including director remuneration, were approximately HKD 6,800,000, compared to HKD 5,600,000 in the previous period, reflecting an increase of about 21.4%[193] - The group has established a share option scheme for employees, with 19,050,000 options remaining unexercised as of September 30, 2024[193] - The stock options granted to 14 business consultants are aimed at providing advice for business development and financial operations[187] Compliance and Standards - The company has not applied new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective, which are not expected to have a significant impact on the financial statements[17] - The company has adopted all new and revised Hong Kong Financial Reporting Standards effective from April 1, 2024, with no significant changes to accounting policies[34] - The financial statements are prepared in accordance with the historical cost convention and presented in thousands of Hong Kong dollars[34] Legal and Contingent Liabilities - The company has no major litigation or contingent liabilities as of the reporting date[192] - There are no significant contingent liabilities as of September 30, 2024[192] - The company has no outstanding stock options available under the 2012 stock option plan as of the reporting date[181]

Financial Performance - The company reported a loss per share of (3.59) HKD for the six months ended September 30, 2024, correcting a previous figure of (3.54) HKD[4] - The weighted average number of ordinary shares used for calculating the basic loss per share is 484,249, not 491,645 as previously stated[12] Financial Reporting Accuracy - The company clarified that the financial period descriptions in the interim results announcement should refer to the six months ended September 30, 2024, rather than June 30, 2024[10] - The company has acknowledged the errors in the interim results announcement and has made necessary clarifications to ensure accuracy[10] - The company will ensure that all future announcements maintain accuracy and clarity in financial reporting[8] Regulatory Compliance - The financial statements for the six months ended September 30, 2024, will be included in the interim report, which will be published in accordance with listing rules[8] - The company is committed to adhering to the listing rules and providing timely disclosures to stakeholders[8] - The interim report will be published in a timely manner as per regulatory requirements[8] Governance Structure - The board of directors includes three executive directors and three independent non-executive directors, ensuring a diverse governance structure[13] Interim Results Summary - The interim results announcement includes a summary of comprehensive income and other comprehensive income for the specified period[3]

Financial Performance - Revenue for the six months ended September 30, 2024, was HKD 18,680,000, compared to HKD 28,268,000 for the same period in 2023, representing a decrease of 33.3%[3] - Gross profit for the period was HKD 1,993,000, down from HKD 5,035,000 in 2023, indicating a decline of 60.5%[3] - The net loss for the period was HKD 17,624,000, compared to a net loss of HKD 16,541,000 in the previous year, reflecting an increase in loss of 6.5%[5] - Total comprehensive loss for the period was HKD 18,130,000, compared to HKD 22,076,000 in 2023, showing a decrease of 17.5%[5] - The company reported a basic and diluted loss per share of HKD 3.54 for the period, compared to HKD 3.19 in the previous year, representing an increase in loss per share of 10.9%[5] - For the six months ended September 30, 2024, the total loss attributable to the company was HKD 63,152,000, compared to a loss of HKD 45,765,000 for the same period in 2023, representing an increase in loss of approximately 38%[14] Revenue Breakdown - Revenue from the medical device and consumables distribution and services segment was HKD 13,209,000, down 39% from HKD 21,808,000 in the previous year[22] - The hospital management services segment generated revenue of HKD 5,471,000, a decrease of 15% from HKD 6,460,000 in the same period last year[22] - The total revenue for the group for the six months ended September 30, 2024, was HKD 18,680,000, down from HKD 28,268,000 in the previous year, indicating a decline of approximately 34%[22] Cash Flow and Liquidity - Cash flow from operating activities for the six months was a net outflow of HKD 11,538,000, compared to an outflow of HKD 14,890,000 in 2023, indicating an improvement of 22.5%[11] - Cash and cash equivalents decreased to HKD 2,409,000 as of September 30, 2024, down from HKD 4,013,000 at the beginning of the period[11] - The company’s total equity as of September 30, 2024, was HKD 51,419,000, compared to HKD 59,753,000 as of the same date in 2023, indicating a decrease of approximately 14%[14] - The current ratio as of September 30, 2024, was 1.08, compared to 1.15 as of March 31, 2024[96] Assets and Liabilities - Non-current assets totaled HKD 62,276,000 as of September 30, 2024, compared to HKD 63,333,000 as of March 31, 2024[7] - Current liabilities increased to HKD 115,282,000 from HKD 112,107,000, reflecting a rise of 2.0%[9] - Total liabilities as of September 30, 2024, were HKD 135,738 thousand, an increase from HKD 132,563 thousand as of March 31, 2024[24] - The asset-liability ratio increased to 0.83 as of September 30, 2024, from 0.11 as of March 31, 2024, due to the inclusion of other payables of approximately HKD 31,100,000[99] Employee and Operational Metrics - As of September 30, 2024, the group employed 118 employees, down from 127 employees as of March 31, 2024[103] - Total employee costs, including director remuneration, were approximately HKD 6,800,000, compared to HKD 5,600,000 in the previous period, reflecting an increase of about 21.4%[103] Legal and Compliance Matters - The company has a contingent liability of USD 4,000,000 (approximately HKD 31,200,000) related to disputed dividends on redeemable convertible cumulative preference shares[49] - The company has ongoing litigation regarding the disputed amount, with a court ruling expected by December 27, 2023[54] - The company has maintained compliance with loan covenants, with no breaches reported as of the latest financial period[44] Strategic Initiatives - The company is enhancing its existing business operations, optimizing its product mix, and seeking new growth points, particularly in the pet vaccine market[67] - The group aims to build a nationwide healthcare distribution platform, leveraging recent government stimulus policies to enhance business opportunities[78] - The board is actively seeking new investors to raise funds and improve cash flow in the second half of the year[77]

Financial Performance - The group reported a significant increase in revenue for the fiscal year ending March 31, 2024, with total revenue reaching HKD 1.2 billion, representing a 15% year-over-year growth[6]. - Revenue for the year ended March 31, 2024, was HKD 59,930,000, a decrease of 21.5% from HKD 76,414,000 in the previous year[57]. - Gross profit for the same period was HKD 13,638,000, down 49.8% from HKD 27,192,000 year-on-year[57]. - The company reported a net loss of HKD 42,497,000 for the year, compared to a net loss of HKD 39,560,000 in the previous year, representing a 4.9% increase in losses[60]. - The total comprehensive loss for the year was HKD 45,951,000, compared to HKD 51,387,000 in the previous year, showing a decrease of 10.6%[60]. - The company's cash and cash equivalents as of March 31, 2024, were approximately HKD 4,000,000, down from HKD 11,500,000 in the previous year[65]. - Current assets were approximately HKD 129,000,000, a decrease from HKD 142,100,000 year-on-year, while current liabilities were approximately HKD 16,900,000, up from HKD 14,900,000[65]. - The debt-to-equity ratio improved to 0.11 from 0.43 in the previous year, indicating a reduction in leverage[69]. - The company incurred a loss attributable to shareholders of approximately HKD 40.2 million, compared to a loss of HKD 42 million in the previous year, with a basic loss per share of HKD 0.0845[120]. - The company recorded revenue of approximately HKD 59.9 million for the fiscal year ending March 31, 2024, a decrease of 21.6% from HKD 76.4 million in the previous fiscal year[119]. User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching 5 million users by the end of the reporting period[6]. - Market expansion plans include entering two new regions, which are projected to increase market share by 5% over the next year[6]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12% based on current market trends and user acquisition strategies[6]. Product Development and Innovation - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on innovative healthcare solutions[6]. - The company is investing HKD 50 million in research and development for new technologies aimed at enhancing service delivery and operational efficiency[6]. - The company is focusing on optimizing its product mix and developing new customers and products to seek new business growth points[125]. - The company aims to leverage advancements in biotechnology and AI technology to enhance its business performance and achieve qualitative leaps in results[115]. Environmental Impact and Sustainability - The group has not used any packaging materials during the reporting period, emphasizing its commitment to environmental protection[30]. - The hospital's waste management showed no harmful waste consumption in 2024, maintaining a focus on sustainability[41]. - The total greenhouse gas emissions increased to 408 tons in 2024 from 294 tons in 2023, reflecting a 38.8% rise in emissions density per million revenue[49]. - The group has implemented energy management measures, including automatic lighting control systems, to reduce unnecessary energy consumption[34]. - The group emphasizes the use of environmentally friendly materials in daily operations to reduce environmental impact[139]. - The company is continuously monitoring waste management processes to ensure compliance with environmental regulations[194]. Operational Efficiency - The group has implemented new strategies to improve operational efficiency, aiming for a 10% reduction in operational costs by the end of the next fiscal year[6]. - The company reported a net profit margin of 12%, reflecting improved cost management and operational efficiencies[6]. - The group achieved a 50% business growth within six months by restructuring the hospital organization and optimizing business processes[27]. Acquisitions and Strategic Partnerships - The company completed the acquisition of 51% of Golden Alliance Limited, which engages in pharmaceutical product distribution and marketing, but did not record any revenue from this acquisition during the year[133]. - The company entered into an agreement to acquire 100% of Jinmei Development Limited for HKD 146 million, to be paid via promissory notes[185]. - The company acquired 51% of Golden Alliance Limited for HKD 153 million, with payment structured through HKD 47.125 million in promissory notes and up to 87.5 million shares at HKD 1.21 each[181]. Employee Management and Training - The company employed 127 staff members, down from 137 in the previous year, with total employee costs increasing to HKD 15,700,000 from HKD 10,200,000[72]. - The training participation rate for male employees is 17.78%, while for female employees it is 2.44%, indicating a significant gender disparity in training engagement[96]. - The group has established a comprehensive training system, ensuring that every employee has opportunities for personal and professional growth[92]. - The group has a policy requiring all employees, including management, to participate in training annually to maintain and enhance their professional skills[96]. Corporate Governance and Compliance - The group has not reported any incidents of forced labor or child labor during the reporting period, demonstrating a commitment to corporate social responsibility[100]. - The group adheres to health and safety regulations, ensuring a safe working environment and providing necessary protective measures to employees[101]. - The group has established a dedicated medical record management department to ensure compliance with privacy protection laws[149]. - No incidents of data privacy violations or significant security events were recorded during the reporting period, reflecting the group's commitment to data protection[154]. Future Outlook and Challenges - The group anticipates recovery and growth in business due to new government incentives and improved business environment, despite facing unprecedented challenges in the past year[173]. - Various risks, including operational and financial risks, may impact the company's financial performance and future outlook[196]. - The management discussion and analysis section provides detailed insights into the company's financial performance and future development plans[200].

中國衛生集團有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此公佈本公司及其附屬公司 （「本集團」）截至二零二四年三月三十一日止年度之綜合業績，連同截至二零二三年三月三十一日 止年度之比較數字如下： | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------------------------------------------------|-------------------| | | 附註 | 截至三月三十一日 \n止年度 \n二零二四年 千港元 | 二零二三年 千港元 | | 除稅前虧損 | 8 | (42,294) | (39,383) | | 所得稅開支 | 9 | (203) | (177) | | 本年度虧損 | | (42,497) | (39,560) | | 以下人士應佔本年度（虧損）╱溢利： 本公司擁有人 非控股權益 | | (40,187) (2,310) | (42,046) 2,486 | | | | (42,497) | ...

Financial Performance - Revenue for the six months ended September 30, 2023, was HKD 30,344,000, a decrease of 6.1% compared to HKD 32,324,000 in the same period of 2022[4] - Gross profit for the same period was HKD 9,275,000, representing a gross margin of 30.6%, compared to HKD 7,111,000 in 2022[4] - The company reported a loss before tax of HKD 16,485,000, an improvement of 40% from a loss of HKD 27,497,000 in the previous year[4] - Total comprehensive loss for the period was HKD 22,076,000, down from HKD 43,490,000 in the same period last year, indicating a 49.3% reduction[7] - The loss attributable to the owners of the company was HKD 27,611,000, compared to HKD 16,541,000 in the previous year[4] - The company reported a basic and diluted loss per share of HKD 6.61, compared to HKD 3.19 in the same period last year[4] - The comprehensive loss for the period was HKD 19,965,000 in 2023, compared to HKD 42,986,000 in the previous period, indicating an improvement in overall financial performance[14] - The group reported a pre-tax loss of HKD 27,497,000 in 2023, compared to a loss of HKD 16,485,000 in 2022, reflecting a worsening of 66.5%[45] - The group reported a loss attributable to shareholders of approximately HKD 5,100,000, an improvement from a loss of HKD 27,600,000 in the previous fiscal period[83] Assets and Liabilities - Non-current assets as of September 30, 2023, totaled HKD 79,050,000, compared to HKD 230,684,000 as of March 31, 2023[10] - Current assets increased to HKD 142,135,000 from HKD 136,670,000, reflecting a growth of 4.3%[10] - Total assets as of September 30, 2023, amounted to HKD 367,354,000, an increase from HKD 221,185,000 as of March 31, 2023[32] - Total liabilities increased to HKD 286,854,000 as of September 30, 2023, compared to HKD 127,235,000 as of March 31, 2023[33] - The total equity as of September 30, 2023, was HKD 80,500,000, compared to HKD 62,524,000 as of September 30, 2022, showing an increase in total equity[14] - The accumulated losses as of September 30, 2023, were HKD (973,594,000), reflecting ongoing challenges in profitability[14] - The group’s total liabilities included HKD 220,795,000 in corporate and other unallocated liabilities as of September 30, 2023[32] Cash Flow - For the six months ended September 30, 2023, the net cash flow used in operating activities was HKD (14,890,000), compared to HKD (5,320,000) for the same period in 2022, indicating a decline in operational cash flow[16] - The net cash flow used in investing activities was HKD (4,726,000) in 2022, with no data provided for 2023[16] - The net cash flow from financing activities decreased to HKD (271,000) in 2023 from HKD 23,098,000 in 2022, reflecting a significant reduction in financing inflows[16] - The total cash and cash equivalents decreased by HKD 8,089,000 in 2023, compared to an increase of HKD 13,052,000 in 2022[16] - As of September 30, 2023, the cash and bank balances stood at HKD 22,746,000, a decrease from HKD 3,255,000 at the same time in 2022[16] - As of September 30, 2023, the group's cash and cash equivalents were approximately HKD 3,300,000, down from HKD 11,500,000 on March 31, 2023[115] Revenue Breakdown - Revenue from medical device and consumables distribution and services reached HKD 21,808,000 in 2023, a slight increase from HKD 21,683,000 in 2022[38] - Revenue from hospital management services was HKD 10,641,000 in 2023, compared to HKD 6,460,000 in 2022, indicating a growth of 65.5%[38] - Total revenue from pharmaceutical product distribution and marketing was HKD 2,076,000 in 2023, while there was no revenue reported in 2022[38] - The total revenue for the group was HKD 30,344,000 in 2023, down from HKD 32,324,000 in 2022, representing a decrease of 6.1%[35] - Revenue from the distribution of medical devices and consumables was approximately HKD 21,800,000, slightly up from HKD 21,700,000 in the previous year[85] - Revenue from hospital management services decreased to approximately HKD 6,500,000 from HKD 10,600,000 in the previous year, resulting in an operating loss of approximately HKD 3,100,000[88] - The group recorded revenue of approximately HKD 2,100,000 from pharmaceutical product distribution and marketing, with an equivalent operating loss[92] Share Capital and Equity - The company issued new shares amounting to HKD 8,925,000 during the period, contributing to the increase in equity[14] - As of September 30, 2023, the company has issued a total of 478,994,763 shares with a capital of 47,900 thousand HKD after a capital reduction[73] - The company completed the acquisition of 51% of Golden Alliance Limited for a total consideration of 153,000,000 HKD, which includes the issuance of shares and promissory notes[75] - The company has undergone a capital reduction, decreasing the par value of shares from 1.00 HKD to 0.10 HKD, effective September 20, 2023[73] - The company proposed a capital reduction by canceling paid-up capital of HKD 0.90 per share, reducing the par value of each issued share from HKD 1.00 to HKD 0.10[109] - After the capital reduction and share split, the authorized share capital will be HKD 10,000,000,000, divided into 100,000,000,000 new shares with a par value of HKD 0.10 each[110] Legal and Regulatory Matters - The company has indicated that the litigation announcement of $4,000,000 is attributed to it, based on the alleged breach of fiduciary duty by former director Li and unauthorized signing of the Capital Foresight agreement[69] - The court ruling regarding the litigation cases HCA2549/2017 and HCA2569/2017 is expected by December 27, 2023[70] - The company is involved in ongoing legal disputes concerning the validity of loan notes issued to Li Hong, which are under serious contention[69] - There were no significant contingent liabilities or major litigation as of September 30, 2023[119][118] Strategic Focus and Future Outlook - The company is focusing on expanding its market presence and enhancing its product offerings to drive future growth[5] - The group continues to operate its commercial factoring business, providing stable income and profits while improving service quality in hospitals[93] - The group has strengthened its existing business, optimized its product portfolio, and sought new growth points, particularly in the promotion of pet vaccines[87] - The healthcare industry in China is expected to continue its diversified growth due to urbanization and aging population, creating significant development potential for the group[95] - The group anticipates business recovery and growth in the second half of the year, supported by new government incentive policies aimed at improving the overall business environment[95] - The group plans to focus on building a nationwide healthcare distribution platform, integrating offline and online resources, and enhancing product offerings in pharmaceuticals, health products, and functional foods[96] Employee and Share Option Information - The total employee cost for the group was approximately HKD 5,600,000, compared to HKD 5,100,000 in the previous period, with 133 employees as of September 30, 2023[122] - The company has 19,050,000 unexercised share options as of September 30, 2023[122] - The 2023 Share Option Scheme allows for the issuance of up to 47,899,476 shares, which is 10% of the total issued shares as of September 30, 2023[134] - No share options were granted, exercised, cancelled, or lapsed under the 2023 Share Option Scheme between September 18, 2023, and September 30, 2023[136] - The 2012 Share Option Scheme remains unchanged during the reporting period[132] - The 2023 Share Option Scheme was approved by shareholders on September 18, 2023, and is effective for 10 years[133]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而 產生或因依賴該等內容而引致之任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 CHGHSLimited （以 名稱在香港經營業務） （於百慕達註冊成立之有限公司） 673 （股份代號： ） 截至二零二三年九月三十日止六個月之 中期業績 中國衛生集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹提呈本公司及其附屬 公司（「本集團」）截至二零二三年九月三十日止六個月（「本期間」）之未經審核簡明綜合中 期財務報表。此等未經審核簡明綜合中期財務報表已由本公司之審核委員會審閱。 ...

Financial Performance - For the fiscal year ending March 31, 2023, the company reported revenue of approximately HKD 54,200,000, a decrease of 39% compared to HKD 88,900,000 in the previous year[31]. - The operating profit for the same period was approximately HKD 5,400,000, down from HKD 8,500,000 in the previous year[31]. - The company experienced a significant decline in revenue from its medical device and consumables distribution business due to COVID-19 restrictions, leading to operational losses for its Wuhan subsidiary[33]. - The company reported a loan and interest impairment loss of approximately HKD 4,000,000, an increase from HKD 2,400,000 in the previous year, with a default probability of 20.1%[27]. - The hospital management services segment generated revenue of approximately HKD 21,200,000, an increase from HKD 18,000,000 in the previous year, with an operating loss of HKD 500,000[34]. - The company reported a loss attributable to shareholders of approximately HKD 42,000,000 for the year, compared to a loss of approximately HKD 12,200,000 in the previous year, indicating a significant increase in losses[43]. - The increase in net loss was primarily due to a fair value change loss of approximately HKD 17,700,000 related to the issuance of consideration shares for the acquisition of a subsidiary, compared to a gain of approximately HKD 4,800,000 in the previous year[43]. - The basic loss per share for the year was HKD 0.0986, compared to HKD 0.0296 in the previous year, reflecting a deterioration in financial performance[43]. - For the fiscal year ending March 31, 2023, the company recorded revenue of approximately HKD 76.4 million, a decrease of 29% from HKD 107 million in the previous fiscal year[67]. - Revenue from medical device and consumable distribution and services was approximately HKD 54.2 million, down from HKD 88.9 million in 2022, representing a decline of 39%[67]. - The company achieved a gross profit of approximately HKD 27.2 million, a decrease of 5% compared to HKD 28.7 million in the previous fiscal year[67]. - Hospital operation and management revenue increased to approximately HKD 21.2 million from HKD 18 million in 2022, reflecting a growth of 17.8%[67]. Assets and Liabilities - As of March 31, 2023, the group's cash and cash equivalents amounted to approximately HKD 11,500,000, an increase from HKD 8,500,000 in 2022[9]. - The group's current assets and net current assets were approximately HKD 142,100,000 and HKD 14,900,000, respectively, compared to HKD 137,700,000 and HKD 800,000 in 2022[9]. - The group's liquidity ratio improved to 1.12 as of March 31, 2023, up from 1.0 in 2022[9]. - The asset-to-liability ratio improved to 0.43 as of March 31, 2023, down from 0.61 in 2022[10]. - The group has a payable dividend amount of approximately USD 4,000,000 (around HKD 31,400,000) for redeemable convertible cumulative preferred shares as of March 31, 2023[9]. Acquisitions and Investments - The group successfully acquired Wuhan Mingcheng Wangda Pharmaceutical Co., Ltd. in June 2023, gaining exclusive distribution rights for an eye medication series in mainland China[13]. - The company acquired 51% stake in Wuhan Mingcheng Wangda Pharmaceutical Co., Ltd. for HKD 153,000,000, with payment structured through a combination of promissory notes and share issuance[21]. - The group invested RMB 30,000,000 in Beijing Qihui Zhiyuan Information Technology Partnership, acquiring a 16.6% partnership interest[17]. - The group holds a 20% stake in Trillion Silver Limited, which focuses on the research, development, and manufacturing of healthcare products, including monkeypox virus rapid test kits[20]. Employee and Governance - The total employee cost for the year was approximately HKD 10.2 million, down from HKD 11.2 million in the previous year, indicating a reduction of about 8.9%[82]. - As of March 31, 2023, the company employed 137 staff, an increase from 122 in the previous year, representing a growth of 12.3%[82]. - The board aims for 25% of its members to be female by the end of 2024, currently working towards gender diversity despite being single-gender at present[75]. - The company has established an employee stock option plan, with 19,050,000 options remaining unexercised as of March 31, 2023[82]. - The company’s board is committed to maintaining and establishing sound corporate governance practices to manage overall business risks effectively[182]. - The board held regular meetings throughout the year to formulate overall strategies and monitor business development and financial performance[198]. - The attendance record for board meetings shows that the executive directors attended all meetings, with a 100% attendance rate[199]. - The independent non-executive directors also demonstrated full attendance in their respective meetings, indicating strong governance practices[199]. Market and Future Outlook - The company plans to optimize its product mix and develop new customers and products to seek new growth points in the post-pandemic era[33]. - The company has identified significant growth potential in the healthcare industry due to urbanization and aging population trends in China[41]. - The company has not provided any future performance guidance or outlook in the current reporting period[150]. - The company has not reported any new product or technology developments in the current financial year[150]. - There are no significant acquisitions or market expansions reported in the current financial year[150]. Compliance and Risk Management - The company has complied with relevant laws and regulations significantly during the year, with no major violations reported[123]. - The company has engaged external consultants to review its risk management and internal control systems, with no significant deficiencies found[78]. - The company’s operations are significantly influenced by political, economic, and legal developments in China, which may pose risks to its business and financial performance[95]. - The company has experienced various risks, including operational and financial risks, which may impact its financial performance and future outlook[120]. - The company is committed to strict adherence to relevant laws and regulations in all its business dealings[198]. Shareholder Information - The total shareholding of Mr. Zhang Fan is 118,107,400 shares, representing 24.66% of the issued shares[134]. - Major shareholder Treasure Wagon Limited holds 116,000,000 shares, accounting for 24.22% of the total issued shares[140]. - The company completed a placement of convertible bonds totaling HKD 40,000,000, which can be converted into 40,000,000 shares at an adjusted conversion price of HKD 1.00 per share[144]. - The net proceeds from the placement amounted to approximately HKD 38,800,000, with HKD 13,800,000 allocated for general working capital and HKD 25,000,000 reserved for potential business development and investments[145]. - The company did not recommend any dividend distribution for the year ended March 31, 2023, consistent with the previous year[124]. - As of March 31, 2023, the company had no reserves available for distribution or physical distribution according to the Bermuda Companies Act 1981[127].